Tweets by @cellcentric

Great to be back in Philly. Collaboration with @SKCCDirector TJU, now looking forward to seeing CCS1477 in the clinic in the US. pic.twitter.com/5PZfeAwkRV

Collaborations were at the heart of initial target ID; also key in translation of our p300/CBP inhibitor into the clinic. pic.twitter.com/sXkV47H5Nd

Will, Karen & Nigel at The Mayo, AZ. Great collaboration with Leif Bergsagel and team: p300/CBP inhibition to treat multiple myeloma. pic.twitter.com/IiKXRyI8gS

CCS1477, first-in-class p300/CBP inhibitor. Targets the conserved bromodomain highly specially, selectively. pic.twitter.com/MCptjO4mIB

First of its kind. CCS1477 p300/CBP inhibitor being trialled in patients with haem malignancies, as well as prostate cancer. pic.twitter.com/Jcl7AXnX9R

ASH now abstracts online: hematology.org/Annual-Meeting… CCS1477 first-in-class p300/CBP inhibitor. #ASH2019 pic.twitter.com/XHyaHoXF2z